McKesson Corporation vs Target Corporation — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Target Corporation trades at $140 (market cap $63.40B). The key difference: McKesson Corporation is the larger of the two by market cap, and Target Corporation pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| MCK | TGT | |
|---|---|---|
Market Cap | $97.35B | $63.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $141.19 |
52-Week Low | $659.01 | $83.68 |
Enterprise Value | $101.98B | $78.70B |
Dividend Yield | 0.39% | 3.32% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Target (TGT) trades at $139.11, down 0.37% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 18.44, P/S of 0.6, and ROE of 22.02%, while revenue remains stable around $106 billion. Positive sentiment is driven by improved traffic trends and merchandising updates noted by Jefferies on July 15, 2026.
Target presents a balanced opportunity with strong profitability and analyst support, though risks include competitive retail pressures and margin volatility. The consensus price target of $137 suggests limited upside, but consistent dividend payments and operational cash flow near $7.4 billion provide stability. Execution on merchandising initiatives will be key for sustained growth.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →